Vasopressin for treatment of shock following aprotinin administration.
OBJECTIVE
To describe the utility of vasopressin in the treatment of acute distributive shock clinically compatible with the diagnosis of aprotinin anaphylaxis.


METHODS
A 57-yr-old female patient underwent repeat cardiac surgery to treat prosthetic valve endocarditis. She had received aprotinin during her first surgery 60 days ago. Despite a negative test dose of i.v. aprotinin 20,000 KIU, when aprotinin loading was initiated during the repeat surgery, the patient developed bronchospasm and hypotension secondary to acute distributive shock. Bronchospasm responded to inhaled salbutamol and ipatropium. The hypotension was refractory to high doses of phenylephrine. Two doses of i.v. vasopressin 5 U reversed the vasodilation and reestablished normal blood pressure.


CONCLUSIONS
Vasopressin, in association with alpha-agonists, can reverse acute refractory distributive shock following aprotinin administration.
Williams
Stephan R
SR
Department of Anesthesiology, Montreal Heart Institute, Montreal, Quebec, Canada.
Denault
André Y
AY
Pellerin
Michel
M
Martineau
Raymond
R
D007611:Aprotinin / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D001986:Bronchial Spasm / Q000188:drug therapy / Q000209:etiology; D002302:Cardiac Output / Q000187:drug effects; D006348:Cardiac Surgical Procedures; D002496:Central Venous Pressure / Q000187:drug effects; D004696:Endocarditis / Q000175:diagnosis / Q000601:surgery; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006350:Heart Valve Prosthesis / Q000009:adverse effects / Q000382:microbiology; D006490:Hemostatics / Q000009:adverse effects*; D006801:Humans; D007022:Hypotension / Q000188:drug therapy / Q000209:etiology; D008875:Middle Aged; D011475:Prosthesis Failure; D012086:Reoperation; D012769:Shock / Q000139:chemically induced / Q000188:drug therapy*; D013203:Staphylococcal Infections / Q000175:diagnosis / Q000601:surgery; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*; D014667:Vasopressins / Q000627:therapeutic use*
D006490:Hemostatics; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D007611:Aprotinin